Tobacco Use Disorders

Deepa R. Camenga, MD, MHSa,*, Jonathan D. Klein, MD, MPHb

INTRODUCTION/BACKGROUND

Tobacco use is a pervasive public health problem and the leading cause of preventable morbidity and mortality in the United States.1 The treatment of adolescent cigarette smoking and tobacco use disorders, in particular, continues to be a substantial public health priority. Adolescence is a critical period for neurodevelopment, and nicotine exposure during adolescence causes addiction, sustained tobacco use into adulthood, and may have lasting adverse consequences for brain development.1–3 Almost all (88%) adult smokers start before the age of 18, and adolescents have difficulty quitting successfully.1 Although rates of cigarette use have decreased in the past decade, according to the Center for Disease Control’s 2014 National Youth Tobacco Survey, 9.2% of high school students and 2.5% of middle school students reported current (past month) cigarette use (Fig. 1).4 Additionally, as rates of cigarette smoking are decreasing, rates of alternative tobacco product (including electronic cigarettes [e-cigarettes] and hookah) and dual (using cigarettes with another product) or polytobacco use (using any 3 or more products) remain prevalent.5,6 Many adolescents are also exposed to second

KEYWORDS

- Smoking
- Tobacco products
- Tobacco use disorder
- Adolescent
- Young adult
- Smoking cessation

KEY POINTS

- Tobacco use is prevalent among adolescents, and alternative tobacco product (ie, electronic cigarettes and hookah) use rates are increasing.
- Adolescents with psychiatric and/or substance use disorders are at particularly high risk of experiencing tobacco dependence and having difficulty with quitting.
- Several practice guidelines recommend that clinicians ask adolescents about tobacco use and provide a strong messages regarding the importance of abstinence from all tobacco products.
- Clinical management of tobacco use consists of behavioral and pharmacologic interventions, which can be used in combination.

INTRODUCTION/BACKGROUND

Tobacco use is a pervasive public health problem and the leading cause of preventable morbidity and mortality in the United States.1 The treatment of adolescent cigarette smoking and tobacco use disorders, in particular, continues to be a substantial public health priority. Adolescence is a critical period for neurodevelopment, and nicotine exposure during adolescence causes addiction, sustained tobacco use into adulthood, and may have lasting adverse consequences for brain development.1–3 Almost all (88%) adult smokers start before the age of 18, and adolescents have difficulty quitting successfully.1 Although rates of cigarette use have decreased in the past decade, according to the Center for Disease Control’s 2014 National Youth Tobacco Survey, 9.2% of high school students and 2.5% of middle school students reported current (past month) cigarette use (Fig. 1).4 Additionally, as rates of cigarette smoking are decreasing, rates of alternative tobacco product (including electronic cigarettes [e-cigarettes] and hookah) and dual (using cigarettes with another product) or polytobacco use (using any 3 or more products) remain prevalent.5,6 Many adolescents are also exposed to second
Adolescents with psychiatric and/or substance use disorders are at particularly high risk for becoming tobacco dependent and are even less likely to quit than other youth.

The 2012 US Surgeon General’s Report “Preventing Tobacco Use among Youth and Young Adults” describes tobacco use as a “multi-determined behavior,” with many biological, psychosocial, and environmental factors influencing its progression. Successful prevention programs have aimed to ameliorate the impact of these factors by promoting self-efficacy and refusal skills and decreasing access to tobacco products; however, tobacco use continues to substantially impact the health and well-being of youth. If smoking continues at the current rate among youth in this country, 5.6 million of today’s Americans younger than 18 (1 out of 13 youth) will die early from a smoking-related illness. This article reviews the epidemiology of tobacco use (including cigarette, alternative tobacco product, and dual/poly-tobacco use patterns) among adolescents and review the highlights of the clinical presentation, diagnosis, and management of tobacco use disorders in youth.

### EPIDEMIOLOGY

#### Cigarette Use

Every day, approximately 3200 youths younger than 18 years old initiate cigarette smoking, and 700 youths begin daily smoking. There has been a decrease in cigarette smoking.

smoking rates over the last 40 years. The decrease in cigarette smoking is likely owing to many factors, including restrictions on advertising, taxation of cigarettes, and smoke-free laws. In 2014, 9.8% of high school students and 2.5% of middle school students reported past month cigarette use. In 2013, 18.9% of 18- to 24-year-olds reported current cigarette use. Historically, cigarettes have been the most common tobacco product that is used exclusively among youth (rather than in combination with another tobacco products). Cigarette smoking rates differ by race/ethnicity as well as geographic regions. In 2013, the prevalence of past month cigarette smoking was higher among white students than black or Hispanic students. Cigarette smoking rates are also higher among youth residing in non-metropolitan areas.

Electronic Cigarettes

E-cigarettes are currently the most commonly used tobacco product by US adolescents. There are several different types of e-cigarettes, including disposable, cartridge, and tank-style e-cigarettes, and adolescents may refer to them by a variety of names including vape pens, e-pens, e-hookah, and vape sticks (Table 1). E-cigarette liquid (“e-juice”) contains nicotine, propylene glycol, vegetable glycerin, flavorants, and various additives. Puffing the e-cigarette (“vaping”) activates a heating element in the atomizer, and the liquid in the cartridge is vaporized into a mist that is inhaled. When youth initiate e-cigarette use, they often start with a flavored e-cigarette. Cartridges with nicotine typically contain 0 to 36 mg of nicotine per milliliter of solution. Therefore, a 5-mL vial of an 18 mg/mL solution contains 90 mg of nicotine. If accidentally or deliberately ingested, this would dose of nicotine could result in intoxication or death.

In 2014, 13.4% of high school students and 3.9% of middle school students reported current e-cigarette use. From 2011 to 2014 the prevalence of ever e-cigarette use tripled among both middle school and high school students, indicating increased experimentation. E-cigarettes especially appeal to cigarette smokers; however, a growing proportion of e-cigarette users are nonsmokers. Leventhal and colleagues demonstrated among a school-based cohort of 14-year-old high school students in Los Angeles, California that, among students who had never used a combustible tobacco product (including cigarettes), ever use of e-cigarettes at baseline (as compared with never use of e-cigarettes) was positively associated with combustible cigarette and hookah use 6 months later. These emerging findings

<table>
<thead>
<tr>
<th>Box 1</th>
<th>Risk factors for tobacco use</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lower socioeconomic status</td>
<td></td>
</tr>
<tr>
<td>• Lower levels of academic achievement</td>
<td></td>
</tr>
<tr>
<td>• High levels of access to tobacco products</td>
<td></td>
</tr>
<tr>
<td>• Lack of skills (self-efficacy, refusal skills) necessary to avoid tobacco</td>
<td></td>
</tr>
<tr>
<td>• Perceptions that tobacco use is normative and not harmful</td>
<td></td>
</tr>
<tr>
<td>• Use of tobacco by significant others and approval of tobacco use among those persons</td>
<td></td>
</tr>
<tr>
<td>• Lack of parental support</td>
<td></td>
</tr>
</tbody>
</table>

Table 1
Electronic cigarettes

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disposable e-cigarette</td>
<td>Cigarette-shaped device consisting of a battery and a cartridge containing an atomizer to heat a solution (with or without nicotine). Not rechargeable or refillable and is intended to be discarded after product stops producing aerosol. Also called an E-hookah.</td>
<td>Njoy, One Joy, Aer Disposable, Flavorvapes</td>
</tr>
<tr>
<td>Rechargeable e-cigarette</td>
<td>Cigarette-shaped device consisting of a battery that connects to an atomizer used to heat a solution typically containing nicotine. Often contains an element that regulates puff duration and/or how many puffs may be taken consecutively.</td>
<td>Blu, Greensmoke, Eonsmoke</td>
</tr>
<tr>
<td>Pen-style, medium-sized rechargeable e-cigarette</td>
<td>Larger than a cigarette, often with a higher capacity battery, may contain a pre-filled cartridge or a refillable cartridge (often called a clearomizer). These devices often come with a manual switch allowing to regulate length and frequency of puffs.</td>
<td>Vapor King Storm, Totally Wicked Tornado</td>
</tr>
<tr>
<td>Tank-style, large-sized rechargeable e-cigarette</td>
<td>Much larger than a cigarette with a higher capacity battery and typically contains a large, refillable cartridge. Often contains manual switches and a battery casing for customizing battery capacity. Can be easily modified.</td>
<td>Volcano Lavatube</td>
</tr>
</tbody>
</table>

Contribute to the public health community’s concern that e-cigarettes may serve as a gateway product to combustible tobacco use, as well as a product with unknown safety and long-term health effects.19,20 The increasing prevalence of e-cigarette use may be attributed to heavy marketing and advertising in youth-dominated media outlets such as social networking and Internet sites, their low price, and the misperception that e-cigarettes are a safer alternative to traditional cigarettes.21,22

**Cigars, Cigarillos, and Little Cigars**

The US Department of the Treasury defines cigars as “any roll of tobacco wrapped in leaf tobacco or in any substance containing tobacco.”23 The US Department of Treasury has classified cigars into 2 types:

1. Little cigars (weighing <3 lb per thousand);
2. Large cigars and cigarillos (weighing more than 3 lb per thousand).

Little cigars are comparable to cigarettes with regard to shape and size, they often have a filter, and adolescents may describe them as cigarettes during a clinical interview.24

According to the 2014 National Youth Tobacco Survey, 8.2% of high school students and 1.9% of middle school students reported current cigar use. The prevalence of current cigar use among high school males (10.8%) was approximately double that of high school females (5.5%).4 The Centers for Disease Control and Prevention recently reported that between 2011 and 2014, cigar use decreased, which reflects the general trend of decreasing popularity of traditional combustible tobacco products among youth.

Cigar use often co-occurs with cigarette use.25,26 The combination of cigars and cigarettes is the most common combination of dual product use among older adolescents and young adults. Similar to e-cigarettes, youth often report that cigars are appealing owing to flavors.14

**Smokeless Tobacco**

Despite recent declines in cigarette use among youths, declines in smokeless tobacco (SLT) have stalled in recent years.2 In the United States, popular forms of SLT have included chewing tobacco or moist snuff. Chewing tobacco is made of long strands of tobacco, whereas snuff tobacco is a fine-grained and comes in a moist blend that usually is used orally.2

Snus and dissolvables are novel SLT products that have become increasingly available over the last 10 years. Snus are made of non-fermented, heat-cured, finely grained tobacco and are spit-free and consumed via pouches, which are placed between the cheek and gum.27 Snus have been used in Sweden since the early 19th century, but were introduced to the United States in 2006.28 Snus are now marketed by major US tobacco companies with cigarette brand names (eg, Marlboro Snus, Camel Snus).28 Dissolvables are another novel SLT that comes in pellets, strips, or sticks. They are designed to be held and dissolved in the mouth for between 3 (strips) and 30 (sticks) minutes.29 Similar to snus, dissolvables were recently introduced in US markets and bear cigarette brand names (eg, Camel Orbs, Camel Strips).30

In 2014, 5.5% of high school students and 1.6% of middle school students reported current SLT use, and a majority used chew/dip. Snus and dissolvables are less popular, with 1.9% and 0.6% of high school students reporting current use, respectively. White males have the highest prevalence of SLT use as measured by multiple national surveys, including the National Survey on Drug Use and Health, Monitoring the Future, and the National Youth Tobacco Survey.4,11,12 Similar to other tobacco products,
advancing age, male cigarette smoking, and perceived friend approval, as well as male gender predict SLT use.31,32

**Hookah**

Hookah, also known as narghile, hubble-bubble, shisha, and waterpipe, delivers a form of combustible tobacco. Commonly flavored, inhaling through the waterpipe pulls the burning tobacco’s smoke through the waterpipe’s water reservoir and then through a tube to which the mouthpiece is attached. Many adolescents believe that hookah smoking is relatively safe.33 Compared with the smoke from a single cigarette, the smoke from one hookah session contains up to 40 times the tar, 2 times the nicotine, 10 times the carbon monoxide and 30 to 50 times the carcinogenic polycyclic aromatic hydrocarbons.33–35

In 2014, 5.4% of high school students and 1.3% of middle school students reported current hookah use,4 with rates increasing between 2011 and 2014. Hookah use increases with age and has increased in popularity among young adults. A survey of a national sample of young adults found that 25% of the sample had ever used hookah and 4% reported use in the past 30 days.26 Predictors of hookah smoking in college and high school students include peer pressure/social acceptability, the perception that hookah is not harmful or addictive, the presence of a family member who uses hookah, and curiosity.26

**Dual Use and Polytobacco Use**

Rates of dual and polytobacco use are increasing. In 2012, 6.7% of middle and high school students reported use of only one tobacco product, while 3.6% reported use of 2 tobacco products and 4.3% reported use of 3 or more tobacco products.6 In 2014, 13% of youth report using 2 or more tobacco products in the past month.6 Compared with those who exclusively use cigarettes, those who use cigarettes and any other form of tobacco are more likely to be male, have greater receptivity to tobacco advertising, and are more likely to use flavored tobacco products.6 Dual use of e-cigarettes and cigarettes in particular is also associated with the use of alcohol and other drugs, rebelliousness, sensation seeking, and behavioral dysregulation.36 Polytobacco use is additionally associated with black, non-Hispanic ethnicity, living with someone who uses tobacco, and perceived prevalence of peers using tobacco.6

**Comorbidity with Mental Health or Developmental Disorders**

Adolescents with mental health or developmental disorders may be particularly vulnerable to tobacco use. This comorbidity may be explained by a common vulnerability to both psychiatric disorders and smoking (familial/genetic or environmental), the need for self-medication, and/or common neurobiological alterations.1 Although the link between mental health disorders and tobacco use has been described extensively in adults, there are few data describing the association among youth. Among adolescents receiving inpatient psychiatric treatment, the prevalence of cigarette smoking has been reported to be as high as 60%.37 A 2002 review by Upadhya and colleagues38 found that adolescent cigarette smoking is highly associated with disorders involving disruptive behavior (such as oppositional defiant disorder, conduct disorder, and attention deficit hyperactivity disorder), major depressive disorders, and drug and alcohol use. More recently, a longitudinal study of 814 adolescent lifetime cigarette smokers assessed the presence of psychiatric disorders with the diagnostic interview schedule for children version IV.39,40 Adolescents and their parents completed 5 waves of data over 2 years. Overall, 33.9% reported any psychiatric disorder (Table 2). Additionally, 60.5% of adolescents meeting Diagnostic and Statistical
Data regarding the temporality of psychiatric disorders and tobacco use remains equivocal. The aforementioned longitudinal cohort of adolescent smokers found that psychiatric disorders (including mood disorders) preceded the onset of tobacco use (1.3–2.4 years lower) and first nicotine dependence criterion (2.5–3.7 years lower). However, a 2009 systematic review of longitudinal studies examining association between depression and smoking in adolescents concluded that the relationship between depression and smoking is bidirectional.

There are only a few studies that examine the co-occurrence of psychiatric disorders with dual use or alternative tobacco product use. A longitudinal cohort study of 486 high school students who reported past month cigarette smoking found that cigar, cigarillo, and little cigar users showed higher levels of depression, anxiety, and antisocial behavior than nonusers, even after adjustment for frequency of cigarette smoking.

---

**Table 2**

<table>
<thead>
<tr>
<th>Psychiatric Disorders</th>
<th>Baseline%</th>
<th>Total%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nicotine dependence</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever 1 criterion</td>
<td>27.9</td>
<td>53.7</td>
</tr>
<tr>
<td>Ever 3 criteria</td>
<td>10.4</td>
<td>26.1</td>
</tr>
<tr>
<td>Total n</td>
<td>(714)</td>
<td>(814)</td>
</tr>
<tr>
<td><strong>Anxiety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social phobia</td>
<td>3.7</td>
<td>6.3</td>
</tr>
<tr>
<td>Panic</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Attacks, no disorder</td>
<td>2.2</td>
<td>3.8</td>
</tr>
<tr>
<td>Disorder</td>
<td>2.6</td>
<td>3.4</td>
</tr>
<tr>
<td>Generalized anxiety</td>
<td>2.3</td>
<td>4.1</td>
</tr>
<tr>
<td>Any anxiety</td>
<td>8.6</td>
<td>14.1</td>
</tr>
<tr>
<td><strong>Mood</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major depression</td>
<td>14.5</td>
<td>17.9</td>
</tr>
<tr>
<td>Dysthymia</td>
<td>1.0</td>
<td>1.7</td>
</tr>
<tr>
<td>Any mood</td>
<td>15.0</td>
<td>18.8</td>
</tr>
<tr>
<td><strong>Disruptive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attention-deficit hyperactivity</td>
<td>2.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Oppositional defiant</td>
<td>11.4</td>
<td>14.2</td>
</tr>
<tr>
<td>Conduct</td>
<td>14.2</td>
<td>21.2</td>
</tr>
<tr>
<td>Any disruptive</td>
<td>21.4</td>
<td>29.5</td>
</tr>
<tr>
<td>Any psychiatric disorder</td>
<td>33.9</td>
<td>43.2</td>
</tr>
<tr>
<td>Total n</td>
<td>(814)</td>
<td>(814)</td>
</tr>
</tbody>
</table>

---

*a* Baseline: wave 3 reports.

*b* Baseline: wave 1 reports.


---

*Manual of Mental Disorders*, fourth edition (DSM-IV), criteria for nicotine dependence reported a history of a psychiatric disorders, whereas only 30.3% of adolescents with 0 symptoms of nicotine dependence reported any psychiatric disorder.

Data regarding the temporality of psychiatric disorders and tobacco use remains equivocal. The aforementioned longitudinal cohort of adolescent smokers found that psychiatric disorders (including mood disorders) preceded the onset of tobacco use (1.3–2.4 years lower) and first nicotine dependence criterion (2.5–3.7 years lower). However, a 2009 systematic review of longitudinal studies examining association between depression and smoking in adolescents concluded that the relationship between depression and smoking is bidirectional. There are only a few studies that examine the co-occurrence of psychiatric disorders with dual use or alternative tobacco product use. A longitudinal cohort study of 486 high school students who reported past month cigarette smoking found that cigar, cigarillo, and little cigar users showed higher levels of depression, anxiety, and antisocial behavior than nonusers, even after adjustment for frequency of cigarette smoking.
**Comorbidity with Substance Use Disorders**

Use of illicit drugs or alcohol greatly increase the likelihood of tobacco use and dependence among adolescents. Studies have found that up to 80% of youth with substance use disorders report past month tobacco use, many report daily smoking, and many become highly dependent, long-term tobacco users. For example, a recent study of 34 substance use treatment programs found that 48% of the 1062 adolescents included met criteria for tobacco dependence, 58% reported weekly tobacco use, and the sample reported a mean of 5 cigarettes smoked per day. Several studies have demonstrated that levels of tobacco use persist despite decreases in alcohol or drug use during substance use treatment, indicating the targeted interventions for smoking cessation are needed for youth receiving substance use treatment.

**CLINICAL PRESENTATION**

The general examination may reveal signs that increase the probability of tobacco use. For example, the presence of smoke-odored clothing, a bottle for chew/dip spit, or cigarette packs may clue the clinician to ask more detailed questions about tobacco use. Adolescents rarely present with clinical signs that are present in adults, such as stained teeth or fingernails, wrinkles, or a hoarse voice. Adolescents in nicotine withdrawal may present with irritability, anxiety, and agitation, and may ask “how long will I be here (because I need to smoke a cigarette)?”

Tobacco contains the psychoactive drug nicotine, which is central nervous system stimulant. The immediate effects of nicotine administration are tachycardia, hypertension, increased respiration, enhanced memory storage, improved concentration, and appetite suppression. Nicotine produces withdrawal symptoms about 1 hour after the last dose. Withdrawal symptoms are not life threatening, are usually self-limited, and include irritability, annoyance, anxiety, and cravings for nicotine.

**DIAGNOSIS**

The primary method of diagnosing tobacco use is through the confidential psychiatric or medical interview. The type of tobacco product used, and the frequency and intensity of use is gauged through adolescent self-report. The 2015 American Academy of Pediatrics’ (AAP) Clinical Practice Policy to Protect Children from Tobacco, Nicotine and Tobacco Smoke endorses several questions from the American College of Chest Physicians Tobacco Treatment Toolkit to screen for and characterize adolescent tobacco use (Box 2). Of note, the clinician should specifically ask about noncigarette

---

**Box 2**

**Questions to screen for the severity of tobacco use in adolescents**

- Do any of your friends use tobacco? Do you use e-cigarettes, e-hookah, or vape? *(This question may help open the conversation, especially for younger adolescents.)*
- Have you ever tried a tobacco product? Which tobacco products have you used? Have you tried an e-cigarette, e-hookah, or vape?
- How many times have you tried (name of tobacco product)?
- How often do you use (name of tobacco product)?

tobacco products, such as hookah and e-cigarettes, because adolescents may not immediately identify them as tobacco products.20

Tobacco Use Disorder is a diagnosis in the fifth edition of the DSM (DSM-5) assigned to individuals who are dependent on the drug nicotine. The DSM-5 replaces the DSM-IV-TR categories of nicotine abuse and dependence with an overarching category called tobacco use disorder. The criteria for DSM-5 tobacco use disorder are the same as those for other substance use disorders. However, adolescents who smoke rarely experience significant social/occupational dysfunction owing to tobacco use, because many of their friends and family members may smoke, thus normalizing the behavior.

Clinicians may choose to assess the severity of cigarette smoking dependence through use of the Hooked on Nicotine Checklist or the modified Fagerstrom Test for Nicotine Dependence (both available through the Alcohol and Drug Abuse Institute-University of Washington Library http://lib.adai.washington.edu/). Adolescents may score positively on these assessments (indicating symptoms of tobacco dependence) soon after they start smoking intermittently, and do not need to be daily or long-term smokers to report signs of addiction.29,46 Data from the 2012 National Youth Tobacco Survey demonstrated that adolescent tobacco users reported symptoms of dependence even with low levels of tobacco use.30

Breath carbon monoxide can be used to assess the presence of smoking in the last 24 hours; however, in practice, it is rarely used outside of intensive smoking cessation treatment programs (such as contingency management–based programs). Cotinine, a metabolite of nicotine, can be found in urine, saliva, and blood for up to 7 days after tobacco use, but is rarely used in clinical practice to guide treatment.

According to the 2006 American Psychiatric Association’s Practice Guideline for Treatment of Patients with Substance Use Disorders,47 additional points should be incorporated into the assessment of tobacco use in patients with psychiatric disorders to determine the appropriate time for treatment initiation (Box 3).

In the case of severe psychiatric comorbidity, the clinician must weigh the risks of benefits of initiating or delaying treatment for tobacco dependence.20,47 Regardless of the timing, all adolescents with comorbid psychiatric disorders should be offered the opportunity to participate in smoking cessation treatment at some point during their psychiatric treatment course.

BRIEF SUMMARY OF CLINICAL MANAGEMENT

Many professional organizations endorse the importance of cigarette and tobacco cessation counseling. The 2006 American Psychiatric Association Substance Use

<table>
<thead>
<tr>
<th>Box 3 Considerations for patients with co-occurring psychiatric disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Psychiatric reasons for concern about whether this is the best time for cessation; that is, new therapies, patient currently in crisis, other pressing psychiatric problem.</td>
</tr>
<tr>
<td>• The likelihood that cessation would worsen the non–nicotine-related psychiatric disorder.</td>
</tr>
<tr>
<td>• Signs or symptoms of other undiagnosed psychiatric or substance use disorders that might interfere with efforts to quit tobacco use.</td>
</tr>
<tr>
<td>• The patient’s current ability to use coping skills for cessation.</td>
</tr>
</tbody>
</table>

Treatment Guidelines encourage mental health clinicians to assess smoking status with all patients and to assist smokers in quitting. Additionally, both the 2008 Public Health Service’s Guideline and the 2015 AAP policy statement on tobacco recommend that all clinicians ask adolescent and young adult patients about tobacco use and provide a strong message regarding the importance of total abstinence from tobacco use. These guidelines acknowledge that smoking cessation may be more difficult for smokers with psychiatric disorders, and treatment may need to be more intensive.

The clinical management of tobacco use consists of behavioral and pharmacologic interventions, which can be used in combination. In general, behaviorally based programs for smoking cessation in adolescents may be most beneficial for adolescents with mild degrees of dependence. The addition of pharmacotherapy can be considered for moderate to severely tobacco-dependent adolescents who want to stop smoking.

**Behavioral Interventions for Tobacco Use Disorders**

Although a comprehensive review of the behavioral interventions for tobacco use disorders is beyond the scope of this review, several systematic reviews have outlined the evidence base surrounding these interventions for adolescents. Stanton and Grimshaw’s 2013 Cochrane Review “Tobacco cessation interventions for young people” found that most studies used complex interventions that incorporated strategies from multiple health behavior theories. Common modalities included motivational enhancement, cognitive–behavioral therapy, and stage-based interventions using the transtheoretical model. The metaanalysis demonstrated that transtheoretical model resulted in a pooled risk ratio of 1.56 at 1 year (95% CI, 1.21–2.01) for cessation, motivational enhancement resulted in a risk ratio of 1.60 (95% CI, 1.28–2.01), and trials of cognitive–behavioral therapy did not result in statistically significant changes in abstinence.

The US Public Health Service 2008 Guideline and the AAP 2015 Clinical Practice Policy recommends brief counseling for treating adolescent smokers. The guidelines recommend the 5A model of care (Ask, Advise, Assess, Assist, Arrange follow-up). In this model, the clinician is encouraged to Ask all adolescents about tobacco use and about secondhand smoke exposure. Next, the clinician should Advise cessation through use of a strong message describing the personal health risks for the patient and the benefits of quitting. Advice should also address protection of oneself and others from secondhand smoke exposure. Through use of the questions/measures described, the clinician should then Assess level of nicotine addiction, as well as readiness to make a quit attempt and/or initiate treatment. Then the clinician should assist the patient in formulating an appropriate tobacco cessation plan, which could include use of behavioral treatments and pharmacotherapy. Last, clinicians should Arrange for follow-up within 2 weeks wherein they discuss the patient’s progress with the quit attempt.

**Pharmacotherapy**

Nicotine replacement therapy (NRT; including patch, gum, inhaler and nasal spray), bupropion, and varenicline are approved for the treatment of smoking cessation in adults (see Table 3). However, there are limited studies that evaluate the efficacy of various pharmacotherapies for adolescent smoking cessation; therefore, the Food and Drug Administration’s labeling indicates these medications for adults older than 18 years.
<table>
<thead>
<tr>
<th>Medication replacement therapy</th>
<th>Dosing</th>
<th>Duration</th>
<th>Adverse Effects</th>
<th>Contraindications</th>
<th>Available</th>
<th>Studied in Adolescents?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicotine replacement therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine patch</td>
<td>If &gt;10 cigarettes/d → 21-mg patch daily; if ≤10 cigarettes/d → 14-mg patch.</td>
<td>8 wk</td>
<td>Local skin reactions, insomnia and/or vivid dreams</td>
<td>Pregnancy,* severe skin conditions</td>
<td>OTC</td>
<td>Yes</td>
</tr>
<tr>
<td>Nicotine gum</td>
<td>4-mg piece if smoking ≥25 cigarettes/d, otherwise 2-mg piece. Use every 1–2 h PRN.</td>
<td>12 wk</td>
<td>Mouth soreness, hiccups, dyspepsia, jaw ache</td>
<td>Pregnancy, unstable angina or arrhythmias</td>
<td>OTC</td>
<td>Yes</td>
</tr>
<tr>
<td>Nicotine lozenge</td>
<td>4-mg lozenge if smoking first cigarette within 30 min of waking, otherwise 2-mg lozenge. Use every 1–2 h PRN.</td>
<td>12 wk</td>
<td>Nausea, hiccups, heartbeat, headache, cough</td>
<td>Pregnancy, unstable angina or arrhythmias</td>
<td>OTC</td>
<td>No</td>
</tr>
<tr>
<td>Nicotine inhaler</td>
<td>1 puff PRN, up to 6–16 cartridges/d.</td>
<td>24 wk</td>
<td>Mouth and throat irritation, cough, rhinitis</td>
<td>Pregnancy, severe reactive airway disease, unstable angina or arrhythmias</td>
<td>Rx</td>
<td>No</td>
</tr>
<tr>
<td>Nicotine nasal spray</td>
<td>1 spray each nostril, every 1–2 h PRN.</td>
<td>12–24 wk</td>
<td>Nasal irritation, nasal congestion, change in sense of smell and taste</td>
<td>Pregnancy, severe reactive airway disease, severe nasal disease, unstable angina or arrhythmias</td>
<td>Rx</td>
<td>Yes</td>
</tr>
<tr>
<td>Nonnicotine replacement therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varenicline</td>
<td>0.5 mg daily × 3 d, then 0.5 mg twice a day × 4 d, then 1 mg twice a day.</td>
<td>12 wk</td>
<td>Nausea, insomnia, vivid dreams; rare cases of agitation, changes in behavior, and suicidal ideation</td>
<td>Pregnancy, use cautiously in patients with psychiatric illness</td>
<td>Rx</td>
<td>No</td>
</tr>
<tr>
<td>Bupropion sustained release</td>
<td>150 mg daily × 3 d, then increase to 150 mg twice a day.</td>
<td>7–12 wk</td>
<td>Insomnia, dry mouth; lowers seizure threshold</td>
<td>Pregnancy, seizure disorder, eating disorder. Use of an MAO inhibitor in the past 14 d</td>
<td>Rx</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Abbreviations:** MAO, monoamine oxide; OTC, over the counter; PRN, as needed; Rx, prescription.

* The 2008 Tobacco Treatment Guidelines suggest that pregnant smokers should be encouraged to quit without medication and should be offered intensive behavioral counseling support at the first prenatal visit and throughout the course of the pregnancy. Nicotine replacement products are FDA pregnancy class D agents. Varenicline and bupropion are FDA pregnancy class C agents.

In 2013, the Cochrane Group for Systemic Reviews reviewed studies evaluating the
efficacy of interventions to promote smoking cessation in youth. The review identi-
fied 1 study evaluating the efficacy of NRT in adolescents who met the inclusion
criteria of being a randomized controlled trial/controlled trial. This double-blind, dou-
ble-dummy, randomized trial of 120 adolescent daily smokers compared nicotine
patch (21 mg), nicotine gum (2 and 4 mg), and a placebo patch and gum. All study par-
ticipants also received cognitive–behavioral group therapy. Intent-to-treat analyses of
all randomized participants showed biochemically confirmed prolonged abstinence
rates of 18% for the active patch group, 6.5% for the active gum group, and 2.5%
for the placebo group, with a statistically significant difference between the patch
and placebo group. A metaanalysis of 8 studies evaluating the efficacy of NRT for
smoking cessation in adolescents found that abstinence rates ranged from 6.5% for
the nicotine gum to 28% for the nicotine patch at 10 weeks; however, these absti-
nence rates were not significant when compared with placebo. Compliance with
NRT varied, ranging from 29% to 85%; however, adverse event rates were low.

The 2013 Cochrane Review also identified 2 studies evaluating bupropion for
adolescent smoking cessation and did not find a benefit of this pharmacotherapy.
Although varenicline is approved for use in adults greater than 18 years (and should
be used with caution in adults with co-occurring psychiatric disorders) there are no cur-
cent published studies of its use in adolescents. Given this evidence, the AAP
recently recommended that clinicians should consider using NRT for adolescents
with moderate to severe substance use disorder. Additionally, given the lack of
data regarding the safety and efficacy of e-cigarettes, the AAP also recommends
that providers advise adolescents that these products should not be used for tobacco
cessation.

CONSIDERATIONS WITH CO-OCCURRING PSYCHIATRIC DISEASE OR SUBSTANCE USE
DISORDERS

There are few published studies evaluating smoking cessation interventions in adoles-
cents with co-occurring psychiatric or substance use disorders. A metaanalysis of
smoking cessation trials in adults with depression, found that the addition of psycho-
social mood management to standard smoking cessation treatment improved long
term abstinence rates in adults with both current and past depression. However,
there are no systematic evaluations of smoking cessation treatments in adolescents
with depression. A randomized trial of 191 adolescents hospitalized in an inpatient
psychiatric unit found similar rates of abstinence when comparing motivational inter-
viewing and brief advice for treating nicotine dependence. At 12 months, quit rates
were 14% and 9% for the motivational intervention and brief advice conditions,
respectively.

A systematic review of 17 studies evaluating smoking cessation treatments among
adults in substance use treatment or recovery found that NRT, behavioral support, and
combination approaches seemed to increase smoking abstinence in those treated for
substance use disorders. However, similar to psychiatric disorders there are few
studies that evaluate effective interventions for adolescents with substance use disor-
ders. For example, a controlled efficacy study of 54 adolescents in substance abuse
treatment compared a 6-session tobacco cessation intervention with a wait-list con-
trol group. Adolescents receiving the tobacco cessation intervention had significantly
greater point prevalence abstinence at 3-month follow-up than did those in the control
group, in addition to fewer days of substance use. Overall, studies in adults and ad-
olescents have shown that tobacco cessation during substance use treatment is
associated with increased abstinence from other substances, decreased substance use overall, and lowered risk for relapse of alcohol and drugs.\textsuperscript{59,60}

**SUMMARY**

Despite great advances in tobacco control, tobacco use and secondhand smoke exposure continues to substantially impact youth. Rates of cigarette use are decreasing; however, use of e-cigarettes, hookah, and other alternative tobacco products are increasing. Youth with psychiatric or substance use disorders are particularly vulnerable to develop tobacco use disorders. All clinicians should screen adolescents for all forms of tobacco use, and provide behavioral and, when indicated, pharmacologic support for quitting. There is a small body of literature evaluating smoking cessation interventions in youth with psychiatric or substance use disorders, and future research should aim to refine smoking cessation techniques for this important population. Given the large body of evidence supporting the deleterious health effects of tobacco use during adolescence, clinicians should give a strong message on the importance of tobacco abstinence.

**REFERENCES**


